Overview

Dose Range Finding Study of Bimagrumab in Sarcopenia

Status:
Completed
Trial end date:
2018-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Blocking
Antibodies, Monoclonal